Loading
Life sciences · Journal article
European Journal of Radiology · October 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Purpose. To assess whether ferumoxytol-enhanced magnetic resonance coronary angiography (CMRA) improves image quality and diagnostic performance compared to non-contrast CMRA, using invasive coronary angiography (ICA) as the reference standard.Methods. This is a retrospective analysis of a prospective trial (ClinicalTrials.gov, NCT05032937). Non-contrast and ferumoxytol-enhanced CMRA were performed on a 3.0 T scanner, with ICA as the gold standard. Two cardiovascular radiologists, blinded to ICA results, independently assessed image quality and diagnostic performance across proximal, middle, and distal coronary artery segments. Contrast-to-noise ratios (CNR) relative to myocardium (CNRmyo) and pericardial fat (CNRfat) were calculated. Sensitivity, specificity, positive and negative predictive value (PPV, NPV), and accuracy were evaluated at the per‑patient, per-vessel, and per‑segment levels.Results. Twenty-nine patients (median age, 64 years, 58.6 % male) were included into final analysis. Ferumoxytol-enhanced CMRA significantly improved CNRmyo and CNRfat across all artery segments. At the per‑patient level, compared with non‑contrast CMRA, ferumoxytol‑enhanced CMRA increased sensitivity from 52.2 % (95 % CI: 30.6 %-73.2 %) to 100 % (95 % CI: 85.2 %-100 %) (p < 0.001), while specificity remained 100 % (95 % CI: 54.1 %-100 %). At the per-segment level (225/261 assessable segments), ferumoxytol‑enhanced CMRA outperformed non‑contrast CMRA, with sensitivity improving from 32.4 % to 88.2 % (p < 0.001), NPV from 89.1 % to 97.9 % (p < 0.001), and accuracy from 88.4 % to 96.9 % (p < 0.001). The diagnostic performance was most pronounced in the middle coronary segments, where sensitivity, PPV, NPV, and accuracy increased from 20.0 %, 50.0 %, 82.6 %, and 80.0 % to 80.0 %, 80.0 %, 95.0 %, and 92.0 %, respectively.Conclusions. Ferumoxytol-enhanced CMRA significantly improved image quality and diagnostic accuracy compared with non‑contrast CMRA, particularly in the middle coronary segments. These findings suggest that ferumoxytol may serve as a viable gadolinium‑free alternative for noninvasive detection of coronary artery disease.